))
A Discussion with Michael Proschan on Response-Adaptive Randomization
Manage episode 501000274 series 3646318
Content provided by Berry. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Berry or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
In this episode of "In the Interim…", Dr. Scott Berry and NIH’s Dr. Michael Proschan conduct a detailed discussion from opposing viewpoints on response-adaptive randomization (RAR) in clinical trials. The discussion focuses on where they agree – on the positives and negatives of RAR, and where they disagree on its scientific use.
Key Highlights
- Potential issues of using RAR: Potential temporal trends, unblinding, reduction in statistical efficiency in 2-arm trials
- Potential benefits include improved statistical efficiency in multi-arm trials depending on the goals (e.g. dose-finding trials).
- Potential unblinding of results in non-blinded trials and the need for operational excellence.
- Ethical and Bayesian perspectives are considered, but emphasis remains empirical.
For more visit: https://www.berryconsultants.com/
27 episodes
Share
